Biodesix, Inc. (BDSX) Stock Score, Valuation & Financial Research
Biodesix, Inc. is in the Healthcare sector and Medical - Diagnostics & Research industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 14/100.
Quick answer for BDSX
Biodesix, Inc. currently has a Wall Street Score of 14/100. The stored market price is $27.4. Its financial score is 25/100. Its valuation score is 0/100. The latest WSS change is -0.1 points. These figures are a research snapshot, not a buy or sell recommendation.
What Biodesix, Inc. does
Biodesix, Inc. is a data-driven diagnostic solutions provider operating across the United States. Its primary focus includes a comprehensive suite of blood-based lung tests, marketed as the Nodify Lung Nodule Risk Assessment (which includes Nodify XL2 and Nodify CDT). These assessments enable clinicians to evaluate the risk of lung cancer in patients with suspicious nodules, aiding in the reclassification of malignancy risk and guiding appropriate treatment pathways. Beyond risk assessment, Biodesix offers additional lung cancer diagnostics such as GeneStrat ddPCR, which detects specific tumor mutations, and VeriStrat, which gauges the patient's immune system status. Both are crucial for establishing prognosis and informing treatment plans. Another offering is the GeneStrat NGS (Next-Generation Sequencing) test, a rapid, blood-based sequencing solution providing results within 72 hours.
BDSX financial snapshot
- Wall Street Score:
- 14/100
- Current price:
- $27.4
- Market capitalization:
- $223.0M
- Revenue:
- $102.9M
- Net income:
- $-27.8M
- Free cash flow:
- $-23.7M
- Cash:
- $30.0M
- Total debt:
- $71.8M
- EPS:
- -3.17
- Financial score:
- 25/100
- Valuation score:
- 0/100
- Revenue score:
- 40/100
What stands out
- Reported year-over-year revenue growth is +0.2%.
- Free cash flow is $-23.7M, showing cash burn in the current stored period.
- The balance sheet shows $30.0M of cash versus $71.8M of total debt, so leverage deserves attention.
- The latest Wall Street Score change is -0.1 points: BDSX decreased 0.1 points because some fundamentals weakened.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 25/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-09.
How to research BDSX
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.